Title

Global solidarity in genomic surveillance improves early detection of
respiratory virus threats

Authors

Simon P.J. de Jong[1], Brooke E. Nichols[2,3,4], Anniek de Ruijter[5], Edyth Parker[6], Vera
Mitesser[6], Christian Happi[6], Menno D. de Jong[1], Alvin X. Han[1*], Colin A. Russell[1*]
7

8 **Affiliations**
9

[1]Department of Medical Microbiology & Infection Prevention, Amsterdam University
Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
[2]Amsterdam Institute for Global Health and Development, Department of Global Health,
Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The
Netherlands
[3]Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
[4]Department of Global Health, Boston University, Boston, MA, USA
[5]Law Centre for Health and Life, Faculty of Law, University of Amsterdam, Amsterdam, The
Netherlands
[6]African Centre of Excellence for Genomics and Infectious Diseases, Ede, Nigeria
20

21 [*]Contributed equally
22

23 Correspondence: c.a.russell@amsterdamumc.nl
24

Abstract

Public health decision-making for respiratory virus outbreaks relies heavily on genomic
sequencing to detect new (variant) viruses. However, respiratory virus sequencing
infrastructure is highly unequally distributed globally, potentially limiting the efficiency and
effectiveness of surveillance efforts and raising concerns about preparedness for future threats.
Using mathematical models, we demonstrate that relative to global sequencing efforts during
the COVID-19 pandemic, increased global solidarity in respiratory virus genomic surveillance
would vastly improve the capacity to rapidly detect novel threats, even with a substantially
reduced number of viruses sequenced globally, leading to improved effectiveness and
efficiency. As a result, the time between a (variant) virus' first global detection and first local
case would increase in all countries, allowing for more time to design and implement global
and local public health measures to mitigate the threat's potential public health impacts. Our
results show that operationalizing global health solidarity is key to guiding investment in
preparedness for future pandemic threats.

Introduction

Genomic surveillance of respiratory viruses is a critical component of public health preparedness and response, particularly for identifying and monitoring the spread of new viruses and their variants[1–3]. According to Article 5 of the International Health Regulations (IHR), Member States to the World Health Organisation (WHO) are obligated to ensure national surveillance capacity[4]. The COVID-19 pandemic represented the zenith of global respiratory virus sequencing output so far, with ~7 million SARS-CoV-2 genomes submitted to GISAID (www.gisaid.org) in 2022 alone. However, this output was highly unequally distributed[5]: half of all publicly shared genomes originated from countries that account for only 4.4% of the global human population while half of the global population accounted for only 0.7% of publicly shared genomes (Fig. 1a, Extended Data Fig. 1). Novel viruses and their variants can potentially emerge in any country. As a result, the unequal distribution of sequencing infrastructure potentially strongly limits the global capacity to rapidly detect novel threats.

Early detection of (variant) viruses such as potential zoonotic reassortant influenza viruses or highly genetically divergent SARS-CoV-2 variants maximises the time available to characterise the threat posed and design and implement potential interventions and mitigation strategies[1,6–8]. Hence, it is paramount for minimising potential public health impacts. To guide efforts toward improved preparedness for future respiratory virus threats, it is important to understand how the global landscape of genomic surveillance capabilities impacts the ability to swiftly identify new respiratory viruses and their variants. Furthermore, planning towards enhanced preparedness requires meaningful minimum sequencing targets as well as functional upper bounds for effective and efficient detection of new (variant) viruses[2,3,5,9–11].

We aimed to quantify how the global distribution of clinical genomic surveillance infrastructure affects the global capacity to rapidly detect and characterize the spread of a novel respiratory virus (variant). First, we used a mathematical model to determine a target minimum global sequencing capacity that balances effective performance and efficient resource use. Then, we leveraged large-scale epidemic simulations to investigate how varyingly solidaristic global distributions of genomic surveillance infrastructure affect surveillance effectiveness. We used 2022 SARS-CoV-2 sequencing output as baseline, representing an empirical pandemic scenario with unprecedentedly high but highly unequally distributed levels of virus genomic sequencing.

Results

Global variation in pandemic-period detection capacity

To investigate how global variation in genomic surveillance capacity impacts the speed of new variant detection, we first investigated the performance of global genomic surveillance efforts for SARS-CoV-2 in 2022, representing an empirical baseline expectation for a potential future pandemic scenario. Sequencing output in 2022 was highly unequally distributed: country-specific sequencing rates estimated from submissions to GISAID[12] ranged from <0.01 sequences per million people per week (S/M/wk) in some countries to >1000 S/M/wk in others (Fig. 1a). The median sequencing rate across European countries

amounted to 64.3 S/M/wk, compared to 0.18 S/M/wk for countries in Africa. Similarly, the
median time from sample collection to deposition in GISAID (henceforth, turnaround time)
ranged across countries from less than a week to hundreds of days (Fig. 1b).

To understand how this variation impacts potential global detection capacity, we used a
global metapopulation model, validated against GLEAM[13,14] (Extended Data Fig. 2), to
simulate hypothetical scenarios of global variant spread and subsequent detection. We
performed 10,000 independent simulations for values of variant R_e ranging from 1.2 to 2. We
assumed a distinct archetypal scenario of variant emergence, characterized by initial R_e and
prevalence of wildtype virus, for each value of variant R_e (Extended Data Fig. 3). In each
simulation, the country where the variant emerged was randomly selected based on a country
population size-weighted probability. We then simulated the time to first variant detection for
each metapopulation epidemic simulation, given empirical country-specific SARS-CoV-2
sequencing rates and turnaround times in 2022 (Fig. 1a,b).

Averaged across simulated variant R_e values, the mean time to first variant detection globally
was 83.0 days (95% CI 18 – 194), with substantial variability especially at lower values of
variant R_e (Fig. 1c). The simulated global number of variant infections by the day of first
global detection varied widely (mean 632,899 infections, 95% CI 77 – 5,917,647), spanning
up to five orders of magnitude for all values of variant R_e (Fig. 1d). In many simulations, new
variants were first detected outside of their continent of origin, driven especially by variants
first emerging in Africa (first detected outside origin continent in 75.0% of simulations), Asia
(23.5%) and South America (19.1%) (Fig. 1e). This means that the variant would have
frequently spread widely within and between continents prior to initial detection (consistent
with, for example, the early spread and detection of the SARS-CoV-2 Omicron BA.1
variant[1]). The continent in which the variant first emerged strongly shaped the time to variant
detection (Fig. 1f) and the number of global variant infections by the day of first detection
(Fig. 1g), the latter ranging from a mean of 23,006 infections (95% CI 29 – 242,943) when
emerging in Europe to 1,757,677 infections (95% CI 1028 – 13,369,527) in case of
emergence in Africa across simulated values of variant R_e. Differences in time to variant
detection were strongly and highly nonlinearly associated with the sequencing capacity in the
country of origin of the novel virus, with low sequencing rates being associated with longer
times to variant detection (Fig. 1h).

Operationalizing global health solidarity

Globally, there is a shared risk of the emergence of pandemic viruses or their variants. In
contrast, the results above indicate the capacity to rapidly detect new (variant) viruses is
profoundly asymmetrically distributed. In part, this imbalance reflects a deficit of global
health solidarity. Solidarity as a principle specifically underlies institutionalized forms of
sharing as a result of mutual dependence[15,16]; it gives guidance to human action in the face of
interdependency related to the shared risks of communicable disease, and underlies the
obligations reflected in the IHR[17,18]. Given that pandemic risk is globally shared, we sought
to investigate how more or less solidaristic approaches to respiratory virus genomic
surveillance could lead to varyingly effective and efficient outcomes for purpose of the global
detection of novel (variant) respiratory viruses. To do so, we specifically considered national

respiratory virus genomic surveillance capacity. We first sought to identify a minimum
sequencing capacity at the national level that could serve as a target toward improving global
capacity for rapid global (variant) virus detection. Ideally, this target would ensure timely
information for public health action as well as efficient use of potentially limited resources. It
would also need to be realistically attainable and sustainable in pandemic and inter-pandemic
periods.

To identify a target minimum global sequencing capacity, we explored the relationship
between sequencing rate, turnaround time, and time to variant detection in any single country
in more detail. Representing a scenario of emergence of a potential future pandemic
respiratory virus (variant), we simulated the emergence of a variant virus in the background
of circulating wildtype virus and computed the expected time to variant detection based on
binomial sampling for different sequencing rates. We then derived a new mathematical model
characterising the relationship between sequencing rates and time to detection of the new
virus variant. For a variant virus, introduced in a population at an initial frequency f_0, where
the change in variant proportion through time can be described by a logistic growth rate s, the
time since variant introduction when the variant virus is expected to have been detected with
confidence level 1-q when sequencing n samples per unit time is equal to
$(\log[(q^{-s/n}-1)/f_0]+1)/s$ (Extended Data Fig. 4). This model is applicable to all respiratory
viruses that can be described by SIR dynamics[19], including SARS-CoV-2, seasonal influenza
virus, respiratory syncytial virus, and potential future pandemic respiratory viruses.

Benefits of increases in sequencing rate are rapidly diminishing

For all modelled scenarios of variant emergence (Extended Data Fig. 3), time to variant
detection rapidly decreased as sequencing rate increased up to ~10 S/M/wk while the benefits
of increases in sequencing rate beyond 10 S/M/wk were much smaller (Fig. 2a, Extended
Data Fig. 5a). In 2022, many high-income countries sequenced SARS-CoV-2 genomes at
rates well in excess of 10 S/M/wk, whereas sequencing rates in many lower-and-middle-
income countries were such that, in absolute terms, small increases would substantially speed
up variant detection (Fig. 2a, Extended Data Fig. 5a). For example, in a country of 100
million people sequencing at the median 2022 SARS-CoV-2 sequencing rate in low-income
countries (0.035 S/M/wk), increasing the sequencing rate by 1 S/M/wk would reduce the time
to detection of a variant with R_e = 1.6 at 95% confidence by ~28 days, given a wildtype
prevalence of 0.5% and a wildtype R_e of 1.1 at time of variant emergence. In contrast, if the
same country was sequencing at the 2022 median high-income country rate (58.9 S/M/wk),
the reduction in time to detection resulting from the same 1 S/M/wk increase in sequencing
rate would be only 3.5 hours (Fig. 2a, Extended Data Fig. 5b). The diminishing returns at
rates characteristic of high-income countries are particularly prominent when looking at the
relationship between sequencing rate and the expected number of variant infections by the
day the variant has been detected (Fig. 2b, Extended Data Fig. 6a). Assuming a 14-day
turnaround time, increasing the sequencing rate in a country sequencing at the median low-
income country rate by 1 S/M/wk would reduce the expected number of variant infections by
the time of detection with 95% confidence by ~4.5 million infections for the scenario of
variant emergence described above; in a country sequencing at the median high-income rate,

the same 1 S/M/wk increase would only reduce the expected number of variant infections by
the day of first detection by ~60 infections (Fig. 2b, Extended Data Fig. 6b).

In addition to sequencing rate, turnaround time is an essential component of effective
genomic surveillance[2,5,20,21]. For reducing time to variant detection, any reduction in
turnaround time is functionally equivalent to a fold increase in sequencing rate (Fig. 2c).
Reductions in turnaround time are especially valuable for the detection of variant viruses that
are highly transmissible. For example, for the archetypal variant with R_e = 2, a three-week
reduction in turnaround time is equivalent to an 89.0-fold increase in sequencing rate (Fig.
2c). Hence, the benefits of increasing sequencing output should be carefully weighed against
the gains from strengthening the ancillary infrastructure necessary for timely availability of
sequencing results.

Using these results, we identified a possible target for a global minimum sequencing
capacity. Given the identified relationship between sequencing rate, turnaround time, and
time to detection, a sequencing capacity of 2 S/M/wk with a two-week turnaround time is a
sensible potential global minimum target (Fig. 2a, vertical grey line). Its position at the elbow
of the relationship between sequencing rate and time to detection (Fig. 2a) suggests that 2
S/M/wk is efficient, and its rapid variant detection even when a highly transmissible variant
emerges in the background of high wildtype prevalence suggests that it results in strong
performance. We chose a relatively low turnaround time of fourteen days given the vital
importance of turnaround time in shaping time to detection. A sequencing rate of 2 S/M/wk
corresponds to 0.18% of the maximum country-specific SARS-CoV-2 sequencing rate in
2022. If all countries sequencing at rates lower than 2 S/M/wk in 2022 were to attain this
minimum capacity, the *de novo* generated sequencing capacity would represent 6.0% of
global sequencing output in 2022. This suggests that in terms of raw sequencing capacity, the
expansion necessary to effectuate the global minimum would be modest compared to
empirical global sequencing output in a pandemic scenario.

Global solidarity improves surveillance effectiveness and efficiency

To model the effect of more solidaristic global genomic surveillance, we re-simulated the
global (variant) virus detection process given the global metapopulation epidemic simulations
in a scenario where all countries possessed a global minimum capacity of at least 2 S/M/wk
with 14-day turnaround time. Ensuring this global minimum sequencing capacity globally
while keeping sequencing output unchanged for countries that already satisfied the minimum
requirement in 2022 (henceforth, strategy A) reduced mean time to global variant detection
by 26.0 days to 57.0 days (95% CI 17 – 119) relative to the simulated 2022 baseline (red bar,
Fig. 3a). The mean number of global variant infections by the day of detection decreased
from 632,899 infections (95% CI 77 – 5,917,647) to 31,485 infections (95% CI 67 – 235,057)
(red bar, Fig. 3b), and the probability that the variant was first detected in its origin continent
increased from 71.0% to 96.4% (red cross, Fig. 3c).

Since reductions in time to detection resulting from increases in sequencing rate beyond ~10
S/M/wk (Fig. 2b) are limited, we further hypothesized that relative to the 2022 baseline,
limiting sequencing rates to 30 S/M/wk would have little detrimental effect on time to variant
detection (Fig. 2a, vertical grey line). In our simulations, setting a 30 S/M/wk upper limit in

all countries relative to the 2022 baseline but no minimum requirement (henceforth, strategy B) left the expected time to first global variant detection (green bar, Fig. 3a) and the expected number of variant infections by the day of detection (green bar, Fig. 3b) largely unchanged: mean time to variant detection increased by only 4.6 days, from mean 83.0 days to 87.6 days (95% CI 22-202) (green bar, Fig. 3a), while global sequencing output was reduced by 67.0%.

To model a globally solidaristic approach to respiratory virus genomic surveillance, we combined the insights that establishing a global minimum sequencing capacity could strongly reduce time to variant detection whereas the reductions in time to detection beyond ~10 S/M/wk rapidly diminish. Simulations indicated that in a hypothetical future pandemic scenario, ensuring a minimum global capacity of 2 S/M/wk, while also setting a 30 S/M/wk upper limit (henceforth, strategy C), could improve time to variant detection by weeks while still reducing sequencing output by 61.0% relative to the 2022 pandemic baseline (blue bar, Fig. 3a, Extended Data Fig. 7). This result suggests that achieving a global minimum surveillance capacity could allow for substantial improvements in the capacity for rapid global virus detection, even with substantially fewer total viruses sequenced globally. We also investigated a scenario of independent country-level expansion, where each country's sequencing output increased proportional to its existing rate. Independently doubling each country's 2022 sequencing output, (strategy D) would only reduce mean time to detection by 7.2 days (brown bar, Fig. 3a, Extended Data Fig. 7), suggesting that siloed expansion of individual countries' sequencing output cannot replace a solidaristic global approach.

Initial detection is a necessary starting point for responses to potential novel threats. However, additional information beyond simple detection is often necessary to characterize the public health risk that a (variant) virus poses. For example, the SARS-CoV-2 Alpha variant was first detected in the UK in a sample collected on 20 September 2020, likely within days of its initial emergence[22]. However, it was not until December 2020 that epidemiological evidence of the variant's transmission advantage relative to pre-existing viruses began to accumulate[22,23]. To that end, we also investigated how a more solidaristic global distribution of sequencing output would affect the time elapsed until the variant would have been estimated to account for a substantial proportion of circulating virus, suggestive of a potential transmission advantage. In our simulations, the time until estimated variant frequencies, in at least one country, provided evidence with 95% confidence that the variant had reached 1% circulating frequency, decreased from 117.7 days (95% CI 42-252) for the 2022 baseline to 103.8 days (95% CI 42-210) for strategy C (Extended Data Fig. 8a). Correspondingly, the mean number of global infections by that day decreased from 2,072,633 (95% CI 4,896-20,293,166) to 205,311 (95% CI 4,873-1,428,529) (Extended Data Fig. 8b). In contrast, capping sequencing rates at 30 S/M/wk (strategy B) increased the mean time until the variant was established to have reached 1% circulating frequency somewhere globally by only 0.5 days relative to the 2022 baseline (Extended Data Fig. 8a). Mathematical models indicate that a sequencing capacity of 2 S/M/wk would ensure robust ascertainment of variant prevalence (Extended Data Fig. 9).

Solidaristic approaches improve opportunities for mitigation

To investigate how establishing a global minimum capacity could affect public health
preparedness, we computed the mean lead time between first global detection and the first
local case for all countries under the different strategies. As the first global detection of a
(variant) virus represents a potential starting point for the design and implementation of local
public health responses, this lead time provides a measure for individual countries of the time
horizon for public health measures that aim to mitigate potential impacts. In all countries, the
lead time would increase under more solidaristic distributions of global sequencing
infrastructure (Fig. 3d), potentially allowing for more time to implement public health
measures in preparation for variant outbreaks or nascent pandemics. For example, for the
archetypal variant virus with R_e = 1.6, the mean time between first global detection and
arrival in the United States was -8.5 days under the 2022 baseline, suggesting that on average,
the variant would already be present in the United States by the time it was first detected
globally. Under the solidaristic strategy C, the public health lead time in the US increased by
two weeks to +6.6 days. The increases in lead time were stronger for lower values of R_e; for
example, for the archetypal variant with R_e = 1.3, the mean lead time increased from +114 to
+144 days in Rwanda, +82 to +111 days in Kazakhstan, +47 to +76 days in Indonesia, and
+21 to +51 days in the United Kingdom, for strategy C relative to the 2022 baseline.

Discussion

Our results indicate that operationalizing global health solidarity in respiratory virus genomic
surveillance could strongly improve preparedness for potential future respiratory virus
threats. Relative to siloed surveillance efforts, where countries' policies are strongly
domestically focused, pursuing sustainable global capacity could substantially reduce the
time to first global detection of variant viruses and the time until variant viruses are found to
exhibit signatures of rapid spread. Initial detection and sequencing is a necessary first step in
assessing and responding to the threat posed by novel viruses and underlies the design and
deployment of countermeasures such as vaccines and therapeutics[7,24]. As such, earlier
warning of potential threats could substantially improve the time horizon for global and local
public health measures that aim to mitigate viral threats' potential impacts, and solidaristic
approaches to global genomic surveillance could improve outbreak preparedness and
response for all countries globally.

Our results suggest that only a small fraction of pandemic-period sequencing output, in the
right places, could transform the global capacity to rapidly detect novel threats. This fact,
combined with the fact that a country can only detect a virus that emerged elsewhere once it
is already present locally, suggests that to improve outbreak preparedness, siloed expansion
of surveillance capacity in countries that already possess strong capacity cannot replace
solidaristic global investment, and that solidaristic approaches to genomic surveillance could
yield greater public health benefit even to countries that already possess strong surveillance
infrastructure locally. Our analyses are primarily focused on detecting novel (variant) viruses
and tracking their spread. Hence, our arguments weighing the enhancement of local
surveillance capacity against the development of basic global capacity do not consider
ancillary benefits of high-intensity genomic surveillance in high-income settings such as
characterization of local transmission dynamics. However, we stress the fundamental

immediate importance of basic global capacity for initial detection for all countries, such as
in the context of vaccine development and deployment, where speed-ups of a few weeks
could have substantial public health impacts globally[25].

In our model we assumed representative sampling in the genomic surveillance process,
including the ready availability and access to diagnostic tools, which does not always hold in
reality[26,27]. As the departure from this assumption is especially strong in resource-constrained
settings[20,26], the reported reductions in time to variant detection resulting from the
establishment of a global minimum sequencing capacity are likely underestimates.
Furthermore, our model does not model the spatial distribution of the minimum capacity in
the country. The spatial distribution of sequencing capacity and the structure of sample
referral networks interplays with turnaround time to shape surveillance performance and
affects the optimal country-level implementation of surveillance networks. Our model is not
applicable to (variant) viruses with no or a detrimental effect on transmissibility such as those
that only result in increased disease severity or reduced sensitivity of diagnostics.
Importantly, our results are robust to biases in the estimates of turnaround time resulting from
delays in sequence deposition in GISAID[28,29] (Extended Data Fig. 10a) and deviations from
the assumed global mobility rates (Extended Data Fig. 10b).

While solidarity is a helpful principle to guide policy in the case of an interdependence of
risks given a particular context, reaching health equity or health justice will require
overcoming substantial challenges[30–35]. Even with the capacity to detect new viruses sooner,
the capacity to respond is also distributed asymmetrically. Even if the proposed models help
undergird global health solidarity, the benefits of more rapidly available vaccines or better-
matched vaccine updates due to timelier detection will only extend to countries with access to
these benefits[30–32,36]. Furthermore, rapidly detecting and sharing information concerning new
(variant) viruses must not paradoxically disadvantage countries that do so. Open sharing of
pathogen genomic data must operate within a system of fair access and benefit-sharing to
achieve its intended public health purpose without exacerbating global health inequity[33,36,37].
Despite these challenges, in many countries there is a desire for enhanced genomic
surveillance capacity to inform local public health responses[21,27,29,38,39].

Given the relationship between turnaround time and sequencing rate, we proposed a
sequencing capacity of 2 S/M/wk with 14-day turnaround time as a target. We note that given
this capacity, the optimal sequencing rate and its balance with turnaround time depends on
the characteristics of the pathogen, the epidemiological background in which the variant were
to emerge, and the required timeliness of sequencing data for public health action; for
example, when levels of wildtype respiratory virus circulation are very low, relatively fewer
sequences might yield a better balance between surveillance performance and resource use.
The proposed target aims to balance the resources necessary for surveillance in periods of
seasonal circulation of respiratory pathogens with the capacity to rapidly detect and scale up
capacity during potential pandemic scenarios. While our study is focused on respiratory
viruses and their variants, leveraging the infrastructure associated with the proposed target for
surveillance of non-respiratory pathogens would yield further benefits. Our results underscore
the importance of turnaround time in shaping the effectiveness and public health utility of

surveillance efforts[20,21], and particularly its balance with sequencing rate. Relieving barriers
to attaining low turnaround times in resource-limited settings, such as the availability of
reagents, is key to realizing the potential benefits of global surveillance capacity[20,40].

While our modelling results provide a principled target that balances resource use and
performance, the optimal design, including the balance of sequencing rate and turnaround
time, will likely differ from country to country, depending on local constraints and priorities.
Our study provides quantitative evidence of how solidaristic approaches provide a rational
basis for improving global surveillance performance, but implementation requires addressing
challenges related to infrastructure, personnel, and funding that currently form barriers to the
implementation of genomic capacity in under-resourced settings[29,40–42]. To achieve the long-
term advancement of global genomics capacity in these settings, coherent capacity-building is
necessary, and that requires sustainable, diversified financing which minimizes dependency
on single funding source while aligning well with national needs[40].

The COVID-19 led to an unprecedented expansion of sequencing capacity globally. Some of
the most consequential gains were made in resource-limited settings[20,21], and it essential that
such gains are maintained and where necessary expanded to maximize preparedness for
future threats. Our results suggest that a global minimum respiratory virus sequencing
capacity offers a path toward improved responses to respiratory virus threats, even for
countries with existing strong national surveillance capacities. For these countries, supporting
a global minimum sequencing capacity could yield benefits in preparation for and during
potential future outbreak scenarios that are not attainable through siloed focuses on local
capacity. Our study shows how a global outlook on pandemic preparedness is essential to
improve both global and local public health. To improve outbreak preparedness, there is no
substitute for global solidarity; it offers a path toward better responses to respiratory virus
threats that would be mutually beneficial to all WHO Member States.
357

Figures

Figure 1. The global time to variant detection based on the SARS-CoV-2 genomic sequencing landscape in 2022.
(A) Distribution of non-zero country-specific weekly sequencing rates per million people by continent estimated from GISAID metadata ($N = 199$) (AF: Africa, EU: Europe, OC: Oceania, AS: Asia, NA: North America, SA: South America). **(B)** Distribution of median country-specific time from sample collection to sequence deposition in GISAID, i.e. turnaround time ($N = 199$). **(C)** The distribution of days to variant detection for different values of variant R_e in global metapopulation model simulations, each with a distinct scenario of variant emergence *($N = 10,000$ for each variant R_e)*. Vertical lines correspond to the median and 95% CI. **(D)** The simulated distribution of the number of global variant infections by the day of first variant detection. **(E)** The simulated probability that the variant is first detected in its origin continent, by origin continent. **(F)** The simulated time to variant detection by variant origin continent. Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. **(G)** The simulated number of global variant infections by the day of detection by variant origin continent, analogous to **F**. **(H)** The relationship between a country's sequencing rate and the mean time to first global detection of a variant emerging in that country in metapopulation simulations ($N = 160$ for each variant R_e). Lines correspond to LOESS fits by variant R_e.

Figure 2. The dependence of time to variant detection on sequencing rate and turnaround time for a single country.

(A) Relationship between sequencing rate and the number of days until the variant will have been detected with 95% confidence. The small black tick marks on the *x*-axes in this plot and in B show country-specific SARS-CoV-2 sequencing rates for 2022. Vertical dotted lines correspond to the median SARS-CoV-2 sequencing rates for high-income (HIC) and low-income (LIC) countries in 2022. In all panels, lines are coloured by values of variant R_e, with a distinct scenario of variant emergence for each value of variant R_e; sequencing turnaround time was assumed to be 14 days. **(B)** Relationship between sequencing rate and the expected number of variant infections by the day the variant will have been detected with 95% confidence. **(C)** Relationship between a reduction in turnaround time (in days) and the fold increase in sequencing rate that would be required to effect the same reduction in time to detection if turnaround time was kept constant.

Figure 3. The time to first global detection of a new variant under varying global distributions of global respiratory virus genomic surveillance infrastructure.
(A) Comparison of time to variant detection for different global strategies for the global distribution of genomic surveillance infrastructure. Each value of variant R_e corresponds to a distinct scenario of variant emergence ($N = 10,000$ for each). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. **(B)** The cumulative number of global variant infections by the day of variant detection by strategy, analogous to A. **(C)** The probability that the variant is first detected in its origin continent, by strategy. **(D)** Comparison of the mean time between the first detection of the variant globally, and the first local within-country infection, by strategy, for individual countries, averaged across values of variant R_e ($N = 195$ for each strategy). Each point corresponds to a country, coloured by continent (AF: Africa, EU: Europe, OC: Oceania, AS: Asia, NA: North America, SA: South America). Boxplots show the median, first and third quartiles, and minimum and maximum values.

Methods

Operationalizing global health solidarity

Genomic surveillance capacity has become a core component of preparedness and response to global disease outbreaks. In accordance with Article 5 and annex 1 of the International Health Regulations (IHR), Member States of the World Health Organization (WHO) must ensure national surveillance capacity. The WHO can assist Member States to develop, strengthen and maintain surveillance capacities as needed (Article 5(4) IHR)[4]. Underlying this obligation is solidarity; a principle that gives guidance to human action in the face of interdependency because of the shared risks of communicable disease[17,18].

Solidarity connotes a sense of commitment to help similar others in need[43]. More specifically solidarity – quite apart from charity or other forms of 'helping out' and sharing – as a principle underlies institutionalized forms of sharing as a result of mutual dependence[15,16]. Solidarity is relational, meaning that its institutional scope is determined by societal bounds of whom we feel solidary towards[44,45]. In the field of health this plays out in national schemes of health insurance, redistribution, planning and rationing to ensure access to medicines and services[46,47].

The relational aspect of solidarity has made it difficult globally to determine what exactly is owed in interstate and global health interactions. In this regard it has been argued that in global health, solidarity needs to be based on 'similarity in a *specific context*'[43]. In line with this presupposition, we operationalize global health solidarity here specifically considering national capacity for genomic sequencing, by modelling for the most effective and efficient global distribution to the extent that we globally face the shared risk of unforeseeable pandemic respiratory virus occurrence. Operationalizing global health solidarity through modelling the global distribution of genomic sequencing capacity in this regard can guide WHO efforts to the implementation of Article 5 IHR, and to rationally invest in genomic sequencing capacity where needed to safeguard global pandemic preparedness as risk-sharing among WHO's Member States.

Sequence metadata analysis

We downloaded metadata corresponding to all SARS-CoV-2 genomes in the GISAID[12] database with collection date from January 1st to December 31st 2022 and submission date before July 1st 2023 ($n = 6,914,601$). For each country with at least one sequence in the dataset, we computed the weekly sequencing rate by dividing the number of viruses sampled in that country by 52 and the country's population size in millions, yielding a sequencing rate in units of sequences per million people per week (S/M/wk). Population sizes for July 1st 2022 were extracted from the United Nations World Population Prospects 2022 (https://population.un.org/wpp/Download/Standard/MostUsed/). For each sequence, we computed the turnaround time from the number of days between the sample collection and submission day in GISAID. We extracted countries' *per capita* gross domestic product (GDP) for 2022, or the most recent year before 2022 if data for 2022 was unavailable, from

457 the World Bank (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD (last updated
458 2023/10/26)). We extracted income classifications for each country for fiscal year 2024 from
459 the World Bank (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-
460 bank-country-and-lending-groups).
461
462 *Variant epidemic simulations*
463
In all analyses, we assumed that a variant virus emerges in the context of circulating wildtype
virus. In our simulations, both variant and wildtype epidemiological dynamics are described
by a susceptible-infected-recovered (SIR) compartmental model with infectious period $1/\gamma$
equal to 5 days for both viruses, with no interactions between genotypes. We simulated
variant epidemics under a range of values of variant R_e at time of introduction (variant R_e =
1.2, 1.3, 1.6, and 2). In the main text, we assumed a different scenario of variant emergence
for each value of variant R_e, characterized by a wildtype (wt) R_e at time of variant
introduction and a wildtype prevalence at time of variant introduction (variant R_e = 1.2: wt R_e
= 1, wt prevalence = 0.1%; variant R_e = 1.3: wt R_e = 1.05, wt prevalence = 0.2%; variant R_e =
1.6: wt R_e = 1.1, wt prevalence = 0.5%; variant R_e = 2: wt R_e = 1, wt prevalence = 2%). These
scenarios were chosen such that circulation dynamics of wildtype and variant were
comparable (e.g. the emergence of a highly transmissible variant in the background of high
wildtype prevalence). In the Extended Data Figures, we show the same analyses for all
combinations of variant R_e and scenario of variant emergence (e.g. a variant with R_e = 2 with
wildtype dynamics corresponding to the scenario for variant R_e = 1.2 (wt R_e = 1, wt
prevalence = 0.1%)). Epidemic dynamics for each scenario in the main text are shown in
Extended Data Fig. 3. While we report results based on variant R_e, we note that results are
primarily dependent on the logistic growth rate of the variant proportion (see section
'*Mathematical model*' below). In this context, the scenario of variant R_e = 2 with wt R_e = 1 is,
for example, functionally equivalent to a scenario with variant R_e = 2.5 and wt R_e = 1.5.
Similarly, the first scenario of variant R_e = 1.2 and wt R_e = 1 is functionally equivalent to a
scenario of variant R_e = 1.6 and wt R_e = 1.3, approximating a scenario of emergence of a
A/H1N1pdm09 pandemic-like virus early in a seasonal influenza virus epidemic.
487
488 *Metapopulation model*
489
490 We used a metapopulation model that couples local SIR dynamics within each index country
491 with global migration to simulate the global spread of a variant. Given a rate of movement
492 w_{nm} from population m to n, the expected number of variant-infected (I_n) and variant-
493 susceptible (S_n) people in population n with population size N_n for a variant with
494 transmission rate β and recovery rate γ, is described by
495

$$\partial_t I_n = \frac{\beta S_n I_n}{N_n} - \gamma I_n + \sum_{m \neq n} (w_{nm} I_m - w_{mn} I_n)$$

$$\partial_t S_n = \frac{-\beta S_n I_n}{N_n} + \sum_{m \neq n} (w_{nm} S_m - w_{mn} S_n)$$

This model is the basis of the model used by Brockmann et al.[48] to fit empirical arrival times
for multiple respiratory viruses to global air transportation data. We used the estimated
pairwise number of trips between all countries from the Global Transnational Mobility
(GTM)[49] to inform w_{nm}. This dataset combines a tourism dataset from the World Tourism
Organization and an origin-final destination dataset corresponding to global air travel data.
Previous work has validated the GTM against the world airline network[50], which Brockmann
et al. [48] showed to strongly reproduce observed dynamics of global pathogen spread.
Specifically, for any two countries n and m we computed w_{nm} by dividing the number of trips
from country m to n in the year 2016 by the population size of country m and by 365. For
each value of variant R_e, we performed 10,000 independent simulations of the
metapopulation model, assuming that the probability a variant virus would emerge in a
particular country is proportional to the country's relative population size (simulations
initialized in Africa: $n = 1793$; Asia: $n = 5946$, Europe: $n = 934$; North America: $n = 739$;
Oceania: $n = 54$; South America: $n = 534$). We integrated the model forward in time at a daily
timescale using a tau-leap algorithm, which also furnishes the epidemic dynamics and global
spread with stochasticity. Each simulation was initialized with an infected population of 10
individuals.

We validated the metapopulation model by comparing arrival times against those that were
independently estimated using GLEAM[14], a separate metapopulation model that incorporates
commuting but which relies on different underlying data. Given an epidemic origin location,
we simulated 10 epidemic instances using the metapopulation model, each initialized with 10
infected individuals, and we simulated 10 instances using GLEAM, where we implemented
the same SIR model. In the GLEAM simulations, we assumed 100% of airline traffic, no
seasonality, and a gravity commuting model with 8 hours spent at the commuting
destinations. For each country, we computed the first day on which median cumulative
incidence across simulations exceeded 0.01 per 1000 individuals for both model
implementations. We performed these simulations for ten countries (Cameroon, Ecuador,
France, Jamaica, Malaysia, Mali, Nepal, Nicaragua, Oman, Uzbekistan) with the GLEAM
model initialized in each country's capital city. For all ten origin locations we find a strong
concordance between arrival times $(r = 0.89$ overall) estimated using the metapopulation
model and GLEAM (Extended Data Fig. 2). This provides support for the use of the
metapopulation model.

Global genomic surveillance simulations

We performed the genomic surveillance simulations using empirical turnaround times and
sampling rates for each country, using data for 2022. For each sequence in GISAID, we
computed the time T between the sample's collection date and submission date. For each
country c, the turnaround-time specific sequencing rate in unit of sequences per day $n_{x,c}$, for
each value of turnaround time x in days, was equal to the country's total sequencing rate in
sequences per day multiplied by the proportion of sequences from that country with $T = x$.

For each country in each simulation, starting from the first day on which the number of new
variant infections exceeded 10 onwards, we deterministically simulated the wildtype
epidemic dynamics. For each value of variant R_e, we assumed a scenario of variant
emergence (characterized by a wildtype prevalence and wildtype R_e) as described above in
the main text. In the Extended Data Figures, we show the same analyses for all combinations
of variant R_e and scenario of variant emergence. Until the first day on which the number of
variant infections exceeded 10, wildtype incidence was assumed to be equal to wildtype
incidence on the first day of the simulated wildtype epidemic, to account for the stochasticity
observed when the number of infections was small and the potential for stochastic variant
extinction.
552
Using the simulated variant and wildtype incidence on each day, we computed the variant
proportion through time $f(t)$. For each country c, on each day t, we used the simulated
country-specific variant proportion $f_c(t)$ to simulate genomic surveillance: For each value of
turnaround time x, we assumed that total sample count $\tilde{n}_{x,c} \sim \text{Poisson}(n_{x,c})$ and simulated the
total number of variant samples $V_c(t) = \sum_{x=0}^{t} v_{x,c}$, with $v_{x,c} \sim \text{Binomial}(\tilde{n}_{x,c}, f_c(t\text{-}x))$. In each
of 10,000 replicate simulations, and for each strategy for the global distribution of
surveillance infrastructure (see next section), we computed the detection day as the first day t
on which $V_c(t)$ was at least one in at least one country c. We defined the detection country as
the first country for which this held.
562
To investigate the time until the variant could be said to account for a substantial proportion
of circulating virus in at least one country, we used the simulated weekly sequence counts to
compute, for each country, if there was any week in the past in which the variant accounted
for at least a proportion π of all samples collected that week with 95% confidence given a
one-tailed binomial test for proportions. We performed this analysis on a weekly basis for
each country, and the day on which the p-value for this binomial test declined below 0.05 in
at least country, for any week in the past, was defined as the day the variant was established
to account for a substantial proportion of circulating virus in at least one country globally. We
chose π to be 1% for all countries with a population of 100 million individuals or fewer. We
ensured a more flexible threshold for countries with a population larger than 100 million. For
these countries, the threshold decreased proportionally as the population size increased, e.g.
using a threshold of 0.5% for a population of 200 million individuals and a threshold of 0.1%
in a population of 1 billion individuals.
576
577 *Global surveillance strategies*
578
579 We investigated five strategies for the global distribution of sequencing infrastructure:
580
581 Strategy 2022: the 2022 baseline. For each country, turnaround time-specific sequencing
582 rates were extracted from GISAID metadata.
583

Strategy A: the 2022 baseline + a global minimum sequencing capacity of 2 S/M/wk with 14-
day turnaround time in each country. If a country already satisfied this requirement (i.e., the
sum of turnaround time-specific sequencing rates with turnaround time ≤14 days was equal to
or greater than 2 S/M/wk), its sequencing rates were unchanged relative to the 2022 baseline.
If a country satisfied the sequencing rate across all values of turnaround time, but not within
the required two-week turnaround time, the deficit in S/M/wk in the sum of turnaround time-
specific sequencing rates with turnaround time ≤14 days was uniformly removed from the
sequencing rates exceeding 14 days and added to the sequencing rate corresponding to a
turnaround time of 14 days. Hence, in this scenario, total sequencing output remained
unchanged, and the minimum sequencing capacity was attained by reducing turnaround time.
If a country did not satisfy the minimum sequencing rate at all, all sequencing output
corresponding to a sequencing rate >14 days was set to a turnaround time of 14 days. The
remaining deficit in S/M/wk in the sum of turnaround time-specific sequencing rates with
turnaround time ≤14 days was added to the sequencing rate corresponding to a turnaround
time of 14 days.
599
600   Strategy B: Equivalent to the 2022 baseline, but individual countries' sequencing output
601   capped at 30 S/M/wk. Countries that sequenced at rates exceeding 30 S/M/wk had their
602   sequencing output capped by dividing sequencing rate uniformly across all values of
603   turnaround time such that total output across all values of turnaround time was equal to 30
604   S/M/wk.
605
606   Strategy C: A combination of strategies A and B. In countries that, after capping according to
607   strategy B, did not satisfy the minimum sequencing rate of 2 S/M/wk with 14-day turnaround
608   time, this minimum was ensured analogous to Strategy A.
609
610   Strategy D: The 2022 baseline, doubled. In each country, the sequencing rate in 2022 was
611   doubled across all values of turnaround time. Hence, the absolute increase in sequencing
612   output was greater in countries that had a higher baseline sequencing rate.
613
614   *Mathematical model*
615
For the single-country analyses presented in Figure 2, we assumed a population of 100
million and turnaround time of two weeks. We deterministically simulated variant and
wildtype epidemics, starting with one variant-infected individual, and computed the variant
proportion *f(t)* through time. For each sequencing rate and given *f(t)*, we computed the
expected day of detection with 95% confidence as the day on which the probability that zero
wildtype sequences would have been binomially sampled up to and including that day
declined below 0.05. On each day, the total number of samples to sequence was assumed to
be a Poisson-valued random variable with rate given by the sequencing rate. For each
sequencing rate, the day of detection was computed as the median across 100 replicates. To
compute the equivalent fold increase in sequencing rate for each reduction in turnaround
time, we computed the slope of a linear model that relates the logarithm of the sequencing
rate to the simulated day of detection for $1 < n < 100$ S/M/wk. In Extended Data Fig. 5 and 6

we show the analyses of time to detection for all combinations of variant R_e and scenario of
variant emergence (e.g. a variant with $R_e = 2$ with wildtype dynamics corresponding to the
scenario for variant $R_e = 1.2$ (wt $R_e = 1$, wt prevalence = 0.1%)).

To mathematically model time to variant detection, we assumed that the variant frequency
follows a logistic growth function, where the proportion $f(t)$ of all new infections at time t
that is attributable to the variant follows:

635
$$f(t) = \frac{1}{1 + \frac{1 - f_0}{f_0} e^{-st}}$$

Here, s is the logistic growth rate that defines the speed at which the variant displaces the
wildtype and f_0 represents the initial variant frequency. The dynamics of logistic growth of
variant proportion characterized the sequential replacement of variants during the COVID-19
pandemic. Assuming no interactions between genotypes, the value of s is equal to the
difference of variant and wildtype exponential growth rates[23]. In reality, s is governed by
factors such as pre-existing immunity in the population and differences in epidemiological
characteristics of variant and wildtype such as their generation interval. Nevertheless, the
derived relationship relies solely on the value of s, and hence is agnostic to the precise
epidemiological characteristics of wildtype and variant. Given these dynamics, we derived a
relationship between the number of viruses to sequence per unit time n and the expected time
until the variant is detected. Beginning with the binomial probability that variant is detected
at or before time step τ:

648
$$P(t \leq \tau) = 1 - \prod_{t=0}^{\tau} [1 - f(t)]^n$$

649   we derived an expression for τ:

650
$$\prod_{t=0}^{\tau} [1 - f(t)]^n = 1 - P(t \leq \tau)$$

651
$$n = \frac{\ln[1 - P(t \leq \tau)]}{\ln\{\prod_{t=0}^{\tau}[1 - f(t)]\}}$$

652   Using the Volterra product integral:

653
$$\prod_{a}^{b} [1 + f(x)dx] = \exp\left(\int_{a}^{b} f(x)\, dx\right)$$

654
$$n = \frac{\ln[1 - P(t \leq \tau)]}{\ln\left[\exp\left(\int_{0}^{\tau} -f(t)\, dt\right)\right]} = \frac{\ln[1 - P(t \leq \tau)]}{-\int_{0}^{\tau} f(t)\, dt}$$

655   Integrating $f(t)$:

656
$$F(t) = \int f(t)\, dt$$

657
$$= \int \frac{1}{1 + \frac{1 - f_0}{f_0} e^{-st}}\, dt$$

658
$$= \int \frac{e^{st}}{e^{st} + \frac{1 - f_0}{f_0}} dt$$

660
$$= \frac{1}{s} \int \frac{1}{e^{st} + \frac{1 - f_0}{f_0}} s e^{st} dt$$

661
$$= \frac{1}{s} \ln \left| e^{st} + \frac{1 - f_0}{f_0} \right| + C$$

662
$$= \frac{1}{s} \ln \left| \frac{f_0(e^{st} - 1) + 1}{f_0} \right| + C$$

664
$$= \frac{1}{s} \ln |f_0(e^{st} - 1) + 1| - \frac{1}{s} \ln \left| \frac{1}{f_0} \right| + C$$

665
$$= \frac{1}{s} \ln(f_0(e^{st} - 1) + 1)$$

666 We can then rewrite:

667
$$n = \frac{\ln[1 - P(t \le \tau)]}{-F(\tau)}$$

668
$$= \frac{s \cdot \ln[1 - P(t \le \tau)]}{-\ln(f_0(e^{s\tau} - 1) + 1)}$$

669
$$\frac{n}{s} = \frac{\ln[1 - P(t \le \tau)]}{-\ln(f_0(e^{s\tau} - 1) + 1)}$$

671 Let $q = 1 - P(t \le \tau)$ which is the probability that the variant will *not* be detected before or
672 during time step τ.

673
$$\text{Ln}(f_0(e^{s\tau} - 1) + 1) = -\frac{s \ln q}{n}$$

674
$$f_0(e^{s\tau} - 1) + 1 = q^{-s/n}$$

676
$$e^{s\tau} = \frac{q^{-s/n} - 1}{f_0} + 1$$

675
$$\tau = \frac{\ln \frac{q^{-s/n} - 1}{f_0} + 1}{s} \quad \text{[Eq. 1]}$$

This equation yields, given s, n, f_0, and q, the day τ on which the variant will have been
detected at least once with confidence level $1 - q$. This equation is valid when the timescales
of detection are smaller than the timescales at which the logistic growth dynamics do not
hold. For example, in extreme scenarios of a very high wildtype R_e, a small variant
transmission advantage and a low sequencing rate, the timescale of variant detection is
beyond that of depletion of the susceptible population and the assumptions of the equation are
not satisfied. We compared the predicted time to detection at 95% confidence for sequencing
rates n ranging from 0.1 to 1000 S/M/wk as computed using epidemic simulations (Fig. 2a in
main text) to predicted time to detection using only Eq. 1. In computing time to detection

using the equation, we used the empirical value of f_0 from the epidemic simulations as input,
with $q = 0.05$. We used the theoretical value of s, computed as (variant R_e - wildtype R_e) / 5.
We performed this simulation for all four scenarios of variant emergence (each corresponding
to a different initial wildtype R_e and wildtype prevalence) and all four values of variant R_e. As
seen in Extended Data Fig. 4, there was high correspondence between the time to detection
from the explicit epidemic simulations and Eq. 1 when the variant R_e was high and/or
wildtype prevalence was low. In contrast, when variant R_e was low and wildtype prevalence
was high, susceptible depletion would occur before the timescale at which the variant would
be detected, and the time to detection as predicted using the equation would deviate from the
simulated time to detection. We note that, for combinations of initial variant proportion and
variant proportion logistic growth rate not explicitly discussed in this study, the mathematical
model can be used to compute the expected time to variant detection.

Variant prevalence estimation

In addition to variant detection, we investigated the relationship between sequencing rates
and the accuracy with which the spread dynamics of the variant can be tracked following its
detection. Specifically, we investigated the accuracy with which the weekly proportion of
new infections that is attributable to the variant can be estimated, and how this accuracy
depends on sequencing rate. Mathematically, assuming a small, finite population N was
infected at prevalence ρ and samples were collected from fraction s of infected individuals
during each week, the potential (finite) number of samples that could be sampled from for
sequencing is $N\rho s$.

Suppose the true circulating proportion is p and n (i.e. $n < N\rho s$) number of samples were
sequenced, the number of variant sequences (X) follows a hypergeometric distribution with
mean and variance:

714
$$E(X) = np$$

715
$$Var(X) = np(1 - p)\left(\frac{N\rho s - n}{N\rho s - 1}\right)$$

716   The variance of the variant proportion $\hat{p}$ ($= X/n$) showing up in the sequences is:

717
$$Var(\hat{p}) = \frac{p(1 - p)}{n}\left(\frac{N\rho s - n}{N\rho s - 1}\right)$$

718   By Central Limit Theorem, $\dfrac{\hat{p} - p}{\sqrt{\frac{p(1-p)}{n}\left(\frac{\rho s N - n}{\rho s N - 1}\right)}}$ follows an approximate Normal distribution.

719   As such, at 95% ($\alpha = 5\%$) confidence, the error (ϵ) around the true variant proportion is:

720
$$\epsilon = Z_{\alpha/2}\sqrt{\frac{p(1 - p)}{n}\left(\frac{N\rho s - n}{N\rho s - 1}\right)}$$

721   For sequencing rate of r sequences per million persons per week (hence $n = \frac{rN}{c}$ where $c =$
722   10^6):

$$\epsilon = Z_{\alpha/2} \sqrt{\frac{p(1-p)}{r}\left(\frac{c\rho s - r}{N\rho s - 1}\right)}$$

724   If $N\rho s$ is sufficiently large (i.e. $N\rho s \gg n = \frac{rN}{c} \rightarrow c\rho s \gg r$),

$$\epsilon \rightarrow Z_{\alpha/2} \sqrt{\frac{p(1-p)}{r}\left(\frac{c}{N}\right)}$$

726   In Extended Data Fig. 9, we visualized the relationship between sequencing rate and the error
727   in the estimated variant proportion, for different population sizes, true variant proportions,
728   and values of α.
729
730   *Sensitivity analyses*
731
In our analyses, we defined a sequence's turnaround time as the time between the sequence's
collection date and its submission date on GISAID. This represents the most accurate
measure of turnaround time available and has been used in previous analyses of global
sequencing output[5]. Nevertheless, a potential issue with this definition of turnaround time is a
lag between acquiring the sequence and its submission to GISAID, which is not reflected in
these estimates[28]; in some cases, sequence analysis might have been performed but the
sequence would only later be deposited in GISAID. To establish the sensitivity of our global
simulation results to such delays in upload to GISAID, we re-simulated our global
metapopulation genomic surveillance simulations, where we assumed that the day the
sequence was acquired was somewhere between the sample's collection date and date of
submission to GISAID. Specifically, for each sequence, we computed the modified
turnaround time as $\phi(t_{submission} - t_{collection})$, for $0 < \phi < 1$. We re-simulated the genomic
surveillance simulation results as presented in Figure 3 for $\phi = 0.25, 0.5$. Varying ϕ modifies
the (country-specific) turnaround time-specific sequencing rates used in the global genomic
surveillance system. Results for different values of ϕ are presented in Extended Data Fig.
10a. For all values of ϕ tested, we find that the conclusion holds that more solidaristic
strategies for the global distribution of respiratory virus surveillance infrastructure (strategies
A and C) offer strongly reduced time to variant detection. Hence, our results are robust to
biases resulting from deviations from the assumption that the submission date represents the
date on which the sample is available. Importantly, the observed consistency between a
country's sequencing rate and its median turnaround time (Spearman's $\rho = -0.60$, $P = 5.1 \times$
10^{-21}) suggests that a country's distribution of turnaround times as computed from GISAID
yields a representative picture of a country's true capacity to rapidly sequence a virus after
sample collection.
756
In our model, we estimated the mobility rate w_{nm} for countries m and n by dividing the
number of trips from m to n in 2016 in the GTM by the population in m. This assumes that all
members of the population participate in disease-relevant spread. In reality, this will not be
the case. However, for the results of our study, these differences are likely to be of little
consequence. Specifically, a lower effective mobility rate would further increase the

reduction in time to detection that would result from the establishment of minimum
sequencing infrastructure globally, as the time until a variant that emerges in a low-
sequencing rate environment is exported to a high-sequencing rate environment would
increase. We explicitly investigated the potential effects of misspecification of the mobility
matrix on our results by multiplying and dividing the mobility rate matrix by three,
representing substantially increased and reduce spread, respectively (Extended Data Fig.
10b). A reduced rate would further increase the gains to be effected by the establishment of
sequencing infrastructure globally. Even if the mobility rate was increased three-fold, the
strategies with increased solidarity in the global distribution of genomic surveillance
infrastructure yield strongly improved performance compared to the 2022 baseline. Hence,
our results are robust to specifics of the mobility dynamics.

Our analyses wholly rely on GISAID data to inform the global landscape of respiratory virus
genomic surveillance infrastructure. In some countries, incomplete or absent deposition of
sequence data in GISAID may result in sequencing rates computed from GISAID data being
unreliable. For example, the zero-covid policy in China that was in place for parts of 2022,
combined with a relatively small number of sequences in GISAID, suggest that submission
rates to GISAID may not accurately represent China's true genomic surveillance capacity[51].
We tested the possible implications of such biases on our results by comparing the results if
all epidemic simulations with new variant viruses originating in China were removed. When
China was removed from the set of possible epidemic origin locations, the conclusions
regarding the performance of the different strategies for the global distribution of genomic
surveillance infrastructure remained unchanged. The representativeness of GISAID data is
further supported by the extremely strong correlation between sequence output and GDP
(Spearman's $\rho = 0.79$, $P = 6.3 \times 10^{-41}$).

Data availability

Data on global population sizes are available from the United Nations World Population
Prospects 2022 (https://population.un.org/wpp/Download/Standard/MostUsed/). Data on
country GDP (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD) and income
classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-
bank-country-and-lending-groups) is available from the World Bank. The Global
Transnational Mobility Dataset is available from the Global Mobilities Project
(https://migrationpolicycentre.eu/globalmobilities/dataset/). Metadata on global SARS-CoV-2
and seasonal influenza virus sequencing rates were extracted from GISAID
(www.gisaid.org). Raw global epidemic simulation output is available at
https://zenodo.org/records/10051237.

Code availability

Custom code and data used to generate the results in this study is publicly available at
https://github.com/AMC-LAEB/genomic_surveillance_solidarity.

References

1. Viana, R. *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature* **603**, 679–686 (2022).
2. Ladner, J. T. & Sahl, J. W. Towards a post-pandemic future for global pathogen genome sequencing. *PLOS Biol.* **21**, e3002225 (2023).
3. Hill, V. *et al.* Toward a global virus genomic surveillance network. *Cell Host Microbe* **31**, 861–873 (2023).
4. World Health Organization (WHO). *International Health Regulations.* (2005).
5. Brito, A. F. *et al.* Global disparities in SARS-CoV-2 genomic surveillance. *Nat. Commun.* **13**, 7003 (2022).
6. Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265–269 (2020).
7. Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516–527 (2020).
8. null, null. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. *N. Engl. J. Med.* **360**, 2605–2615 (2024).
9. Wohl, S., Lee, E. C., DiPrete, B. L. & Lessler, J. Sample size calculations for pathogen variant surveillance in the presence of biological and systematic biases. *Cell Reports Med.* **4**, (2023).
10. Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and challenges in virus genomic epidemiology. *Trends Parasitol.* **37**, 1038–1049 (2021).
11. Méder, Z. Z. & Somogyi, R. Optimal capacity sharing for global genomic surveillance. *Epidemics* **43**, 100690 (2023).
12. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* vol. 22 at https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494 (2017).
13. Balcan, D. *et al.* Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. *BMC Med.* **7**, 45 (2009).
14. Broeck, W. Van den *et al.* The GLEaMviz computational tool, a publicly available software to explore realistic epidemic spreading scenarios at the global scale. *BMC Infect. Dis.* **11**, 37 (2011).
15. Sangiovanni, Andrea; Viehoff, J. Solidarity in Social and Political Philosophy. in *The Stanford Encyclopedia of Philosophy (Summer 2023, Metaphysics Research Lab, Stanford University 2023).*
16. Prainsack, Barbara; Buyx, A. Solidarity: Reflections on an Emerging Concept in Bioethics. *Nuff. Counc. Bioeth.* (2011).
17. Taylor, A. L. *et al.* Solidarity in the wake of COVID-19: reimagining the International Health Regulations. *Lancet* **396**, 82–83 (2020).
18. Toebes, B., Forman, L. & Bartolini, G. Toward Human Rights-Consistent Responses to Health Emergencies: What Is the Overlap between Core Right to Health Obligations and Core International Health Regulation Capacities? *Health Hum. Rights* **22**, 99–111 (2020).
19. Boyle, L. *et al.* Selective sweeps in SARS-CoV-2 variant competition. *Proc. Natl. Acad. Sci.* **119**, e2213879119 (2022).
20. Wilkinson, E. *et al.* A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. *Science (80-.).* **374**, 423–431 (2021).
21. Tegally, H. *et al.* The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. *Science (80-.).* **378**, eabq5358 (2023).

857   22.   Hill, V. *et al.* The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in
858   the UK. *Virus Evol.* **8**, veac080 (2022).
859   23.   Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage
860   B.1.1.7 in England. *Science (80-.).* **372**, eabg3055 (2021).
861   24.   Anderson, A. S. A lightspeed approach to pandemic drug development. *Nat. Med.* **28**,
862   1538 (2022).
863   25.   Newland, M. *et al.* Improving pandemic preparedness through better, faster influenza
864   vaccines. *Expert Rev. Vaccines* **20**, 235–242 (2021).
865   26.   Han, A. X. *et al.* SARS-CoV-2 diagnostic testing rates determine the sensitivity of
866   genomic surveillance programs. *Nat. Genet.* **55**, 26–33 (2023).
867   27.   Salyer, S. J. *et al.* The first and second waves of the COVID-19 pandemic in Africa: a
868   cross-sectional study. *Lancet* **397**, 1265–1275 (2021).
869   28.   Kalia, K., Saberwal, G. & Sharma, G. The lag in SARS-CoV-2 genome submissions to
870   GISAID. *Nat. Biotechnol.* **39**, 1058–1060 (2021).
871   29.   Sahadeo, N. S. D. *et al.* Implementation of genomic surveillance of SARS-CoV-2 in
872   the Caribbean: Lessons learned for sustainability in resource-limited settings. *PLOS*
873   *Glob. Public Heal.* **3**, e0001455 (2023).
874   30.   Lavery, J. V, Porter, R. M. & Addiss, D. G. Cascading failures in COVID-19 vaccine
875   equity. *Science (80-.).* **380**, 460–462 (2023).
876   31.   Wouters, O. J. *et al.* Challenges in ensuring global access to COVID-19 vaccines:
877   production, affordability, allocation, and deployment. *Lancet* **397**, 1023–1034 (2021).
878   32.   Ortiz, J. R. & Neuzil, K. M. Influenza Immunization in Low- and Middle-Income
879   Countries: Preparing for Next-Generation Influenza Vaccines. *J. Infect. Dis.* **219**, S97–
880   S106 (2019).
881   33.   Moodley, K. *et al.* Ethics and governance challenges related to genomic data sharing in
882   southern Africa: the case of SARS-CoV-2. *Lancet Glob. Heal.* **10**, e1855–e1859
883   (2022).
884   34.   Ramsay, M. African genomic data sharing and the struggle for equitable benefit.
885   *Patterns* **3**, 100412 (2022).
886   35.   Preiser, W., Engelbrecht, S. & Maponga, T. No point in travel bans if countries with
887   poor surveillance are ignored. *Lancet* **399**, 1224 (2022).
888   36.   Carlson, C. *et al.* Save lives in the next pandemic: ensure vaccine equity now. *Nature*
889   **626**, 952–953 (2024).
890   37.   Lancet, T. The Pandemic Treaty: shameful and unjust. *Lancet* **403**, 781 (2024).
891   38.   Olawoye, I. B. *et al.* Emergence and spread of two SARS-CoV-2 variants of interest in
892   Nigeria. *Nat. Commun.* **14**, 811 (2023).
893   39.   Mashe, T. *et al.* Genomic epidemiology and the role of international and regional
894   travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely
895   collected surveillance data. *Lancet Glob. Heal.* **9**, e1658–e1666 (2021).
896   40.   Olono, A., Mitesser, V., Happi, A. & Happi, C. Building genomic capacity for
897   precision health in Africa. *Nat. Med.* (2024) doi:10.1038/s41591-024-03081-9.
898   41.   Onywera, H. *et al.* Boosting pathogen genomics and bioinformatics workforce in
899   Africa. *Lancet Infect. Dis.* **24**, e106–e112 (2024).
900   42.   Omotoso, O. E. *et al.* Bridging the genomic data gap in Africa: implications for global
901   disease burdens. *Global. Health* **18**, 103 (2022).
902   43.   West-Oram, P. G. N. & Buyx, A. Global Health Solidarity. *Public Health Ethics* **10**,
903   212–224 (2017).
904   44.   Prainsack, B. & Buyx, A. *Solidarity in Biomedicine and Beyond. Cambridge Bioethics*
905   *and Law* (Cambridge University Press, 2017). doi:DOI: 10.1017/9781139696593.
45.   James, Chris; Savedoff, W. Risk Pooling and Redistribution in Health Care: An

Analysis of Attitudes toward Solidarity. in *World Health Report (2010) Background*
paper No. 5 (2010).
46.   Genschel, Philipp; Hemerijck, A. Solidarity in Europe. in *01 EUI Policy Brief.* (2018).
47.   Baute, S. & de Ruijter, A. EU health solidarity in times of crisis: explaining public
preferences towards EU risk pooling for medicines. *J. Eur. Public Policy* **29**, 1183–
1205 (2022).
48.   Brockmann, D. & Helbing, D. The Hidden Geometry of Complex, Network-Driven
Contagion Phenomena. *Science (80-.).* **342**, 1337–1342 (2013).
49.   Deutschmann, E., Recchi, E. & Vespe, M. Assessing Transnational Human Mobility
on a Global Scale BT - Migration Research in a Digitized World: Using Innovative
Technology to Tackle Methodological Challenges. in (eds. Pötzschke, S. & Rinken, S.)
169–192 (Springer International Publishing, 2022). doi:10.1007/978-3-031-01319-5_9.
50.   Klamser, P. P. *et al.* Inferring country-specific import risk of diseases from the world
air transportation network. *arXiv e-prints* arXiv:2304.12087 at
https://doi.org/10.48550/arXiv.2304.12087 (2023).
51.   Preiser, W. & Maponga, T. So far, no novel SARS-CoV-2 variants from
Beijing—and hopefully better scientific cooperation going forward. *Lancet*
401, 621–622 (2023).
925

926
927
Extended Data Fig 1. The global distribution of sequencing output.
(A) The cumulative proportion of the global population that accounts for a cumulative
proportion of global sequence output for SARS-CoV-2. Data on sequencing output
corresponds to SARS-CoV-2 sequences in GISAID with collection date in 2022. Solid grey
lines show the smallest proportion of the population that accounts for 50% of sequencing
output. Dashed grey lines show the smallest proportion of sequencing output that is
accounted for by 50% of the global population. **(B)** The cumulative proportion of the global
population that accounts for a cumulative proportion of global seasonal influenza sequence
output. Data on sequencing output corresponds to seasonal influenza sequences collected
from humans in GISAID with collection date in 2018. Solid grey lines show the smallest
proportion of the population that accounts for 50% of sequencing output. Dashed grey lines
show the smallest proportion of sequencing output that is accounted for by 50% of the global
population.
941
942
943

945
Extended Data Fig. 2. Validation of the metapopulation model against GLEAM. For ten
geographically representative countries, global variant spread was simulated, initialized in the
country's capital city, in GLEAM. For each of the 10 index countries, all global countries'
epidemic onset timings as simulated using GLEAM were compared against the countries'
epidemic onset timings as simulated using the epidemic model used in this study. For both
models, timings were computed as the median across 10 independent simulations.
Simulations are for a variant R_e of 1.6.
953

954
955
956 **Extended Data Fig. 3. Different scenarios of variant emergence.** For each of the values of
957 variant R_e, the corresponding panel shows the epidemiological dynamics of variant and
958 wildtype for that scenario of variant emergence, starting from the day of variant introduction.
959 For each value of variant R_e, the scenario of variant emergence is characterized by a different
960 value of wildtype R_e and wildtype prevalence at introduction.
961

962
Extended Data Fig. 4. Validation of derived time to variant detection. The red points
show the relationship between time to detection simulated using binomial sampling (*x*-axis)
and time to detection computed using the derived mathematical model (*y*-axis). The dashed
grey line corresponds to *y*=*x*. Each panel corresponds to a different variant R_e and different
scenario of variant emergence (i.e. a different value of wildtype R_e and wildtype prevalence
at time of variant introduction). This illustrates that the equation is valid, unless the
timescales of detection are smaller than the timescales at which the logistic growth dynamics
do not hold (bottom left quadrant), e.g. when susceptible depletion occurs before the variant
is expected to be detected (see Methods).
972
973
974

Extended Data Fig. 5. The dependence of time to variant detection on sequencing rate for varying scenario of variant emergence. (A) Relationship between sequencing rate and the number of days until the variant will have been detected with 95% confidence. The small black tick marks on the *x*-axes in this plot and in **B** show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a different scenario of variant emergence, characterized by a wildtype (wt) R_e and wildtype prevalence at introduction. In each panel, lines are colored by value of variant R_e. **(B)** Relationship between sequencing rate and the reduction in time to variant detection that results from increasing the existing sequencing rate (*x*-axis) by 1 S/M/wk.

987
Extended Data Fig. 6. The dependence of the number of variant infections by day of
detection on sequencing rate for varying scenario of variant emergence. (A) Relationship
between sequencing rate and the number of infections by the day the variant will have been
detected with 95% confidence. The small black tick marks on the *x*-axes in this plot and in **B**
show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a
different scenario of variant emergence, characterized by a wildtype (wt) R_e and wildtype
prevalence at introduction. In each panel, lines are colored by value of variant R_e. **(B)**
Relationship between sequencing rate and the reduction in the number of variant infections
by the day of variant detection that results from increasing the existing sequencing rate (*x*-
axis) by 1 S/M/wk.
998

1000
Extended Data Fig. 7. Time to global variant detection by strategy and scenario of variant emergence. (A) Time to global variant detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant R_e, for varying scenario of variant emergence (characterized by wildtype (wt) R_e and wildtype prevalence ($N = 10,000$ for each). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. **(B)** Number of global variant infections by the day of first detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant R_e, for varying scenario of variant emergence (characterized by wildtype (wt) R_e and wildtype prevalence).

1010
Extended Data Fig. 8. Time to ascertainment of substantial variant proportion by
strategy and scenario of variant emergence. **(A)** Time until the variant was found to
account for a substantial proportion of circulating virus in at least one country, by strategy for
the global distribution of respiratory virus surveillance infrastructure, by variant R_e, for
varying scenario of variant emergence (characterized by wildtype (wt) R_e and wildtype
prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points
correspond to means. **(B)** Number of global variant infections by the day the variant was
found to account for a substantial proportion of circulating virus in at least one country, by
strategy for the global distribution of respiratory virus surveillance infrastructure, by variant
R_e, for varying scenario of variant emergence (characterized by wildtype (wt) R_e and wildtype
prevalence).
1022

1023

Extended Data Fig. 9. The relationship between sequencing rate and error in estimated variant proportion. For each sequencing rate given on the *x*-axis, for varying true variant proportion and population size, the *y*-axis shows the maximum error in the estimated weekly proportion of total infections attributable to the variant. This maximum error is presented for varying confidence (i.e. the *y*-axis represents the error that the error in the estimated variant proportion relative to the true variant proportion will be smaller than *n*% of the time, for *n* given by the confidence level).

1036
Extended Data Fig. 10. Sensitivity analyses for time to detection.
(A) Sensitivity analysis for time to GISAID submission. Time to global variant detection by
strategy for the global distribution of respiratory virus surveillance infrastructure, by variant
R_e, for varying scenario of variant emergence (characterized by wildtype (wt) R_e and wildtype
prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points
correspond to means. Given a sequence in GISAID's computed turnaround time T, a
sequence's adjusted turnaround time $\tilde{T}$ was equal to ϕT. These adjusted turnaround times
were used to inform country-specific sequencing infrastructure in the global genomic
surveillance simulations. **(B)** Sensitivity analysis for mobility rate. Time to global variant
detection by strategy for the global distribution of respiratory virus surveillance
infrastructure, by variant Re, for varying scenario of variant emergence (characterized by
wildtype (wt) Re and wildtype prevalence). Thin and thick lines correspond to 95% and 50%
CIs, respectively. Points correspond to means. Each row corresponds to a modified global

mobility rate (top: baseline mobility rate multiplied by 3; bottom: baseline mobility rate
divided by 3).
1052